These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7850057)

  • 61. [A study of the clinical usefulness of the CA15-3 radioimmunoassay kit].
    Abe Y; Odagiri E; Jibiki K; Demura R; Demura H
    Gan No Rinsho; 1988 Oct; 34(12):1672-6. PubMed ID: 3193612
    [TBL] [Abstract][Full Text] [Related]  

  • 62. BCM-IMx and CA15.3 serum levels in patients with breast cancer: a comparative study.
    Allende MT; Fernández Llana B; Rodriguez Alvarez JM; Roiz MC; Vizoso F; Ruibal A
    Bull Cancer; 1991; 78(8):743-5. PubMed ID: 1932840
    [No Abstract]   [Full Text] [Related]  

  • 63. Relationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions.
    Atoum M; Nimer N; Abdeldayem S; Nasr H
    Asian Pac J Cancer Prev; 2012; 13(3):857-60. PubMed ID: 22631661
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serum transcobalamin II levels in breast carcinoma patients.
    Rachmilewitz B; Sulkes A; Rachmilewitz M; Fuks Z
    Isr J Med Sci; 1981; 17(9-10):874-8. PubMed ID: 7309476
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Clinical study of CA15-3 in human breast cancer].
    Nihei M; Nomizu T; Tsuchiya A; Abe R
    Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):987-95. PubMed ID: 3480326
    [No Abstract]   [Full Text] [Related]  

  • 66. [CA15-3].
    Matsui A; Ikeda T; Masamura S; Kitajima M
    Nihon Rinsho; 1999 Dec; 57 Suppl():474-7. PubMed ID: 10778168
    [No Abstract]   [Full Text] [Related]  

  • 67. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System.
    Molina R; Gion M; Gressner A; Troalen F; Auge JM; Holdenrieder S; Zancan M; Wycislo M; Stieber P
    Clin Chem Lab Med; 2008; 46(5):612-22. PubMed ID: 18598203
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Significance of ca15-3 in carcinoma of the breast with Visceral metastases.
    ; Haider G; Shaikh Z; Memon P; Shahid A; Rahul R; Kumar P; Beg S; Parkash J
    J Ayub Med Coll Abbottabad; 2023; 35(Suppl 1)(4):S710-S714. PubMed ID: 38406898
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game.
    Gion M; Boracchi P; Dittadi R; Biganzoli E; Peloso L; Mione R; Gatti C; Paccagnella A; Marubini E
    Eur J Cancer; 2002 Jun; 38(9):1181-8. PubMed ID: 12044503
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Are preoperative serum CA15-3 levels different in breast cancer subgroups?
    Araz M; Beypinar I; Kazan S; Inci F; Celiker M; Uysal M
    Curr Probl Cancer; 2019 Apr; 43(2):115-122. PubMed ID: 30104028
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer.
    Sacks NP; Stacker SA; Thompson CH; Collins JP; Russell IS; Sullivan JA; McKenzie IF
    Br J Cancer; 1987 Dec; 56(6):820-4. PubMed ID: 2449238
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessment of four monoclonal antibodies as serum markers in breast cancer.
    Robertson JF; Pearson D; Price MR; Selby C; Badley RA; Pearson J; Blamey RW; Howell A
    Eur J Cancer; 1990; 26(11-12):1127-32. PubMed ID: 2149994
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer.
    Tkaczuk KHR; Hawkins D; Yue B; Hicks D; Tait N; Serrero G
    Clin Breast Cancer; 2020 Jun; 20(3):220-227. PubMed ID: 31928925
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma.
    Terävä J; Tiainen L; Lamminmäki U; Kellokumpu-Lehtinen PL; Pettersson K; Gidwani K
    PLoS One; 2019; 14(7):e0219480. PubMed ID: 31344060
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of bone scan with carbohydrate antigen 15-3 for evaluation of bone metastasis of brest cancer.
    Mohammadzadeh M; Alikhah H; Zareh AG
    Pak J Biol Sci; 2010 Feb; 13(4):175-9. PubMed ID: 20437684
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.
    Keshaviah A; Dellapasqua S; Rotmensz N; Lindtner J; Crivellari D; Collins J; Colleoni M; Thürlimann B; Mendiola C; Aebi S; Price KN; Pagani O; Simoncini E; Castiglione Gertsch M; Gelber RD; Coates AS; Goldhirsch A
    Ann Oncol; 2007 Apr; 18(4):701-8. PubMed ID: 17237474
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature.
    de Larrea CF; Cibeira MT; Vallansot R; Colomo L; Bladé J
    Clin Lymphoma Myeloma; 2008 Oct; 8(5):312-4. PubMed ID: 18854288
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Positive correlation of serum uridine diphosphate-galactosyltransferase levels with breast carcinoma.
    Paone JF; Waalkes TP; Baker RR; Shaper JH
    Surg Forum; 1978; 29():158-60. PubMed ID: 122607
    [No Abstract]   [Full Text] [Related]  

  • 79. [CA15-3].
    Inaji H
    Nihon Rinsho; 2010 Jul; 68 Suppl 7():691-3. PubMed ID: 20963903
    [No Abstract]   [Full Text] [Related]  

  • 80. Elevation of CA15-3 caused by a benign tumour.
    Ghnassia JP; Rodier JF; Eber M
    Lancet Oncol; 2001 Feb; 2(2):102. PubMed ID: 11905789
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.